AMENDMENTS

In the Claims:

Claims 1-2. (Canceled).

3. (Currently amended) A compound of formula II,



II

wherein

Ar^1	is ~~selected from the group consisting of~~ phenyl, ~~pyridinyl, quinolinyl, isoquinolinyl, thiophenyl, benzothiadiazolyl, isoxazolyl and oxazolyl,~~
Ar^2	is pyridinyl,
R^6, R^7	are independently H or A,
R^8, R^9 and R^{10}	are independently selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$, $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$,

$(CH_2)_nCOOR^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $(CH_2)_nN(R^{11})C(R^{13})HCOR^{11}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{11}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{13}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{13})COOR^{14}$, $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$, $(CH_2)_nN(CH_2CONH_2)COOR^{13}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$, $(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$, wherein

R^{11}, R^{12} are independently selected from the group consisting of H, A and (CH_2),

R^{13}, R^{14} are independently selected from the group consisting of H, Hal, A and $(CH_2)_mAr^4$,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

Ar^3, Ar^4 are independently aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from the group consisting of A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, NR^{15} $CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from the group consisting of H, A, and $(CH_2)_mAr^6$, wherein

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X is O ~~or CH_2~~,

Y is O or S ~~selected from O and S~~,

p, r are independently 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,

u is 0, 1, 2 or 3,

and

Hal is selected from the group consisting of F, Cl, Br and I;

and a pharmaceutically acceptable salt ~~derivatives, salts and solvates~~ thereof.

4. (Currently Amended) The compound according to claim 3, selected from the compounds of formula IIc, IIe, IIg, IIh, ~~Iii,~~ IIi and IIj, ~~IIk, IIL, IIm, IIn, IIo, IIp, IIq, IIr, IIs, IIt, IIu, IIv, IIw and IIx,~~



IIc



IIe



IIg



IIh



IIi



IIj



~~IIk~~



~~IIL~~



~~IIm~~



~~IIn~~



~~IIo~~



~~IIp~~



~~IIq~~



~~IIr~~



~~IIs~~



~~IIt~~



~~IIu~~



~~IIv~~



~~IIw~~



~~IIx~~

wherein R^6, R^7, R^8, p, Ar^1, Y, X, R^9, R^{10} and q are as defined in claim 3 and a pharmaceutically acceptable salt thereof ~~pharmaceutically acceptable salts and solvates thereof~~.

5. (Currently amended) The compound according to claim ~~1~~ 3, selected from the compounds (1) to (2), (5) to (224) of table 1, the compounds (225) to (226), (229) to (448) ~~(449)~~ of table 2 and/or the compounds (449) ~~(450)~~ to (450) and (453) to (672) of table 3, and a pharmaceutically acceptable salt thereof ~~pharmaceutically acceptable salts and solvates thereof~~.

Claims 6-9. (Canceled).

10. (Currently Amended) A pharmaceutical composition, comprising the compound according to claim 3 in a pharmaceutical composition and further comprising an inert carrier.

Claims 11-29. (Canceled).

30. (Withdrawn/Previously presented) A method for producing compounds of formula II, wherein

a) a compound of formula III



III

wherein

FG is a functional group, selected from
–N=C=Y and –NH-(C=Y)-LG,
wherein Y is as defined as in claim 3 and LG is a leaving group,

is reacted

b) with a compound of IV,



IV

wherein

L^2, L^3 are independently from one another H or a metal ion, and R^6, R^7, E, G, M, Q, U, R^9, q, X, Ar^2, R^{10} and r are as defined in claim 3,

and optionally

c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

Claims 31-32. (Canceled).